Skip to main content
Premium Trial:

Request an Annual Quote

Clontech to Stop Selling RNase H Line After Settlement With Invitrogen

NEW YORK (GenomeWeb News) — Clontech will stop selling its RNase H minus reverse transcriptase products as part of a settlement reached last week with Invitrogen.
Invitrogen sued Clontech more than a decade ago for infringing two of its US patents — numbers 5,244,797 and 5,668,005 — that cover embodiments of the firm's reverse transcriptases. Invitrogen added two more of its US patents, numbers 6,063,608 and 5,405,776, to the suit later. All of the intellectual property relates to mutations that disable the RNase H activity of native reverse transcriptase
The settlement came after an undisclosed jury decision last week in a federal district court in Maryland. As part of the settlement, Clontech agreed that Invitrogen's patents in the case are "valid and enforceable."
Further details of the agreement were not disclosed.
Clontech is a wholly owned subsidiary of Takara Bio.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.